Aurobindo recalls empty epilepsy capsules

By Fiona Barry

- Last updated on GMT

Gabapentin capsules were distributed with no contents (Picture: Bill Brooks)
Gabapentin capsules were distributed with no contents (Picture: Bill Brooks)

Related tags: Medicine

Aurobindo Pharma has recalled one lot of Gabapentin for the treatment of epilepsy and postherpetic neuralgia (pain after shingles), after it was found to contain empty capsules.

The 300mg products are packaged in 100-count bottles, NDC 16714-662-01, with ‘D’ imprinted on a yellow cap and ‘03’ on the yellow body with black edible ink. The affected lot, GESB14011-A, was distributed through Northstar label to pharmacies in the US.

The company said empty capsules could result in missed doses, with possible adverse consequences ranging from no effect to life-threatening seizures.

So far it has received four complaints about empty capsules, but no adverse event reports.

Aurobindo, based in India, manufactures therapies for neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporin indications for global markets.

Related topics: Contract Manufacturing & Logistics

Related news

Show more

Follow us

Products

View more

Webinars